Navigation Links
Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T
Date:9/12/2013

econd subject there was a transient suppression of VL at or below LOQ. The subject remains off ART.

A third subject completed the TI with 1-log decrease in VL from peak.
In three subjects, there was no reduction in VL during the TI, one completed the TI and in two the TI was terminated early due to their viral loads exceeding the upper limit allowed in the protocol.
A seventh subject has not completed TI and is still being evaluated.

The non-employee authors of these abstracts have no financial relationship with Sangamo.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and it has also established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic&re
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences to Acquire Ceregene
2. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
3. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
4. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
5. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
6. Sangamo BioSciences Reports First Quarter 2013 Financial Results
7. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
8. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
9. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
10. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
11. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:7/9/2014)... There has been a sharp increase in the number ... MyChart, the online, interactive service that allows patients to ... providers, schedule appointments, and renew prescriptions. , Over a ... MyChart each year increased five-fold, while the number ... according to a study by Dr. David Gerber ...
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... may smell of flatulence and have a reputation for being ... hydrogen sulfide is now being being found to offer potential ... stroke, heart attacks and dementia. A new compound (AP39), designed ... key to future therapies, by targeting delivery of very small ... inside cells. , Scientists in Exeter have already found ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... VANCOUVER, Jan. 30 /PRNewswire-FirstCall/ - QLT Inc. ("QLT") (NASDAQ: ... its modified "Dutch Auction" tender offer (the "Offer"), which expired ... QLT has accepted for purchase and cancellation 20,000,000 of its ... Share, for a total cost of US$50 million. The purchased ...
... (Nasdaq: LCAV ), a leading provider of laser ... announced that it will release fourth quarter and full year ... 10, 2009. A conference call and webcast to discuss ... 2009 at 10:00 a.m. Eastern time.To access the conference call, ...
... CEO of America,s Health Insurance Plans (AHIP), today issued ... to reauthorize and expand the State Children,s Health Insurance ... is an essential component of comprehensive health care reform. ... by voting to help ensure that no child falls ...
... classified by the government as overweight, and with ... even more difficult for people to lose weight, ... MD from Russia ( www.drolga.com ) offers clients ... on CD at www.drolga.com and through ...
... certification allows pharmacies using the Company,s POS product to comply with ... , ... Fountain Valley, CA (PRWEB) January 30, 2009-- ... of Sale software has received SIGIS (Special Interest Group - IIAS ...
... division of HCPro, Inc., announced today the ... website that provides the pharmaceutical and medical ... educate staff and maintain compliance with government ... training products offered by ePharmaceuticals™ into one ...
Cached Medicine News:Health News:QLT announces final results of tender offer 2Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 2Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 3Health News:CAM Pharmacy Point of Sale Software Receives SIGIS Certification for IIAS Compliance 2Health News:CAM Pharmacy Point of Sale Software Receives SIGIS Certification for IIAS Compliance 3Health News:ePharmaceuticals™ Announces the Launch of epharmcomply.com 2Health News:ePharmaceuticals™ Announces the Launch of epharmcomply.com 3Health News:ePharmaceuticals™ Announces the Launch of epharmcomply.com 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: